Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity College, London

About this trial

The investigators will recruit up to 20 volunteers with chronic, supra-sacral SCI. Following screening, eligible participants will enter 'Phase I', they will complete baseline outcome measures and then have the epidural spinal cord stimulator (eSCS) implanted with either percutaneous or paddle electrodes. Preoperative and intraoperative testing will determine exact location of electrodes.

Mapping and optimisation of stimulation parameters will be performed simultaneously with urodynamic investigations of bladder function, and anorectal physiology investigations of bowel function. The acute effects of eSCS to suppress bladder overactivity, facilitate voiding, prevent unwanted reflex sphincter activity, and pelvic floor function will guide development of eSCS programmes for use at home.

In 'Phase II', participants will use eSCS at home for 12-weeks. Participants will also be taught how to perform bladder and pelvic floor muscle training (PFMT) in combination with eSCS.

Outcome measures assessing bladder, bowel, sexual function, quality of life, motor function and spasticity will be captured prior to and following the 12-week intervention, and at 3 and 6 month follow up.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Spinal Cord Injury (supra-sacral)

AIS A-D

>18 years;

SCI sustained >12 months ago;

Disqualifiers

Transected cord or SCI related to a neurodegenerative disease

Any device or metal work in situ that would exclude the patient from having eSCS implanted

Intra-detrusor botulinum toxin injections within the last 6 months

Previous surgical intervention on bladder sphincters

Trial design

Design model

Single group

Treatments tested in this trial

  • Epidural Spinal Cord Stimulation

    Device

    Epidural Spinal Cord Stimulation Mapping and Pelvic Floor Muscle Training

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: TreatmentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Maximum Cystometric Capacity (bladder capacity) from baseline (week 1) to post intervention (week 16) and follow up (week 28, week 40)

During standard cystometry (retrograde filling of the bladder), maximum cystometric capacity will be defined as the volume emptied from the bladder after each fill.

Time frame
Week 1, 16, 28 and 40

Secondary outcomes

1

Maximum Detrusor Pressure

Maximum recorded detrusor pressure during standard cystometry (retrograde filling of the bladder).

Time frame
Week 1, 16, 28 and 40
2

Rectal and Anal Pressure during Push Manoeuvre

During standard anorectal physiology, London protocol.

Time frame
Week 3, 16, 28 and 40
3

3 day bladder diary

Bladder diary will be completed on clinically used bladder diaries. Participants will record voided volumes, urinary incontinence episodes and daily spasticity for 3 days. This will involve measuring the volume voided each time they urinate over the three days, using provided measuring equipment.

Time frame
Week 3, 12, 16, 28 and 40
4

Up to 14 day bowel diary

Bowel diary will be completed on clinically used bowel diaries. Participants will record type of stool and amount, bowel incontience, bowel management e.g laxatives, use of manual evacuation.

Time frame
Week 3, 12, 16, 28 and 40

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University College, London

Lead sponsor

Royal National Orthopaedic Hospital NHS Trust

Collaborator